According to a recent LinkedIn post from Xeltis, the company is highlighting clinical and commercial visibility activities around its aXess regenerative hemodialysis conduit at the VASA 2026 meeting in Salt Lake City. The post notes that Dr. Jason Wagner is presenting 12‑month pivotal data from a 120‑patient E.U. multicenter study in an Innovation/Best Abstracts session, alongside Xeltis’ role as a sponsor and exhibitor.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post also references an internal U.S. clinical coordinators working session focused on implementing a regenerative hemodialysis conduit in practice. The description of aXess as a scaffold that is cannulation‑ready at implantation and gradually transforms into the patient’s own vessel suggests Xeltis is positioning the platform as a differentiated vascular access solution, which could support long‑term adoption prospects if clinical outcomes remain favorable.
For investors, the emphasis on 12‑month pivotal data and engagement with both European and U.S. clinical teams points to continued advancement of the aXess program toward broader commercialization. Increased exposure at a specialized vascular access conference may help build KOL support and accelerate trial enrollment and eventual market uptake, potentially enhancing Xeltis’ competitive standing in the hemodialysis access and renal care device segment.